Mark Senak, Fleishman-Hillard
Mark Senak, SVP for Fleishman-Hillard and author of Eye on FDA blog, discusses ways that pharma companies can engage in social media. Recorded at exl Pharma’s Digital Pharma Conference.
Some of Mark’s VlogViews:
“So much of the time what people are tied up about is that this is new media and there are new rules. There aren’t new rules, it’s the same old rules with new media. And people just haven’t grasped that yet.”
“It’s not the medium, it’s the message. If you’re going to say something like it’s ok to use a drug off label online, you’re going to get a warning letter. But if you’re going to talk about a product in the same responsible way that you would in a DTC or a print ad, as long as you meet regulatory guidelines, you’re not going to have a trip wire effect on regulatory.”
“If you can demonstrate that you are making effective inroads through the use of Youtube video in the risk associated with a particular drug, that’s a tremendous tool that’s much more targeted then say, putting something on television where you’re shot gunning a huge audience. With Youtube you are actually getting an in to the people who are looking for that information.”
Fleishman-Hillard
Eye on FDA
Search Terms: Mark Senak, Fleishman-Hillard, Eye on FDA, FDA, pharmaceutical companies, social media, digital pharma, exl Pharma